Revvity (RVTY) reported $695.9 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 36.1%. EPS of $1.25 for the same period compares to $1.70 a year ago. ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 The Company reported GAAP earnings per share of $0.64, as compared to $1.01 in the same period a year ago. GAAP revenue for the quarter was $696 million, as compared to $741 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $77 million, as compared to $137 million for the s ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024. “I am pleased to welcome Michael Klobuchar and Sophie Vandebroek to Revvity’s board and look forward to their contributions as we execute on our strategic vision,” said Alexis Michas, non-executive chairman of the board. “Sophie brings deep acumen in AI, business processes, sustainability, and cybersecurity, alon ...

Revvity, Inc. (NYSE:RVTY) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 1:30 PM ET Company Participants Prahlad Singh - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Chase & Co. Rachel Vatnsdal Hi, good afternoon, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team here at JP Morgan. I am joined on stage by Revvity and Prahlad, the CEO. And so as is typical, this is going to be a 40 minute session, it will be roug ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q _______________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 1, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-5075 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q _______________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 2, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-5075 ___ ...

Revenue Performance - Total revenue for Q1 2023 was $674.9 million, a decrease of $288.3 million, or 29.9%, compared to Q1 2022[86] - Diagnostics segment revenue fell to $346.6 million, down $310.6 million, or 47%, primarily due to decreased demand for COVID-19 products[93] - Life Sciences segment revenue increased to $328.4 million, up $22.4 million, or 7%, driven by growth in pharmaceutical and biotechnology markets[101] Margins and Expenses - Consolidated gross margins decreased by 524 basis points to 56.5% in Q1 2023, primarily due to lower COVID-19 revenue[87] - Operating margins dropped from 27% to 11% in Q1 2023, with expectations of approximately 30% for the full fiscal year[87] - Selling, general and administrative expenses decreased by $26.7 million, or 10%, to $248.6 million in Q1 2023[95] - Research and development expenses were $56.7 million, a slight decrease of $0.8 million, or 1%, compared to Q1 2022[97] Income and Taxation - The effective tax rate from continuing operations was 15.6% for Q1 2023, down from 18.2% in Q1 2022[100] - Segment operating income for Life Sciences increased by $19.3 million, or 17%, to $129.5 million in Q1 2023[102] - Segment operating income for the three months ended April 2, 2023, was $74.4 million, a decrease of 75% from $300.9 million for the same period in 2022[104] Cash Flow and Investments - Net cash provided by operating activities for the three months ended April 2, 2023, was $71.7 million, down from $326.1 million for the same period in 2022, a decrease of $254.4 million[120] - Net cash used in investing activities was $215.1 million for the three months ended April 2, 2023, compared to $48.6 million for the same period in 2022, an increase of $166.5 million[121] - Net cash used in financing activities decreased to $113.2 million for the three months ended April 2, 2023, from $164.9 million in the same period in 2022, a decrease of $51.7 million[122] Share Repurchase and Dividends - The company repurchased 450,238 shares of common stock for an aggregate cost of $57.9 million during the three months ended April 2, 2023[116] - A quarterly cash dividend of $0.07 per share was declared for Q1 FY 2023, with $8.8 million accrued for dividends declared on January 26, 2023, to be paid in May 2023[124] - The company may consider reducing or eliminating its common stock dividend in the future to fund growth investments, repurchase shares, or conserve capital resources[124] Cash and Contingent Considerations - As of April 2, 2023, the company had cash and cash equivalents of $2.3 billion, with $1.9 billion held by non-U.S. subsidiaries[113] - The company recorded contingent consideration obligations of $43.8 million related to acquisitions with open contingency periods as of April 2, 2023[117] - The company expects to use proceeds from the sale of the business for debt maturities, share repurchases, and strategic acquisitions[110] Debt Management and Market Risks - The company has repurchased $32.9 million of its 0.550% senior unsecured notes due in September 2023 and $81.9 million of its 0.850% senior unsecured notes due in September 2024 since the beginning of Q3 FY 2022[123] - The company continues to measure foreign currency risk using the Value-at-Risk model, with no material changes in the measures for its Value-at-Risk analysis[128] - The company is exposed to market risks, including changes in interest rates and currency exchange rates, and manages these risks through derivative transactions[127] - The sensitivity measures for the company's interest rate risk have not changed materially, as detailed in its 2022 Form 10-K[130] - No derivative instruments are outstanding as of April 2, 2023, to manage interest rate exposures[129] Accounting and Regulatory Matters - The company has not adopted any new accounting pronouncements during the three months ended April 2, 2023, and no significant impact from recently issued accounting pronouncements is expected[126]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q _______________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 2, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-5075 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q _______________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 3, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-5075 ___ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q _______________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 3, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-5075 __ ...